Cumberland Pharmaceuticals (CPIX) said late Tuesday it will collaborate with Qureight to enhance the output of its Phase 2 trial evaluating the ifetroban drug candidate for idiopathic pulmonary fibrosis.

Under the collaboration, Cumberland will use Qureight's artificial intelligence-based image analytics tools to extract deeper insights into treatment efficacy and disease progression.

The Phase 2 trial includes 128 patients, both on existing antifibrotic therapies and those not receiving similar treatments. The primary endpoint focuses on change in forced vital capacity, the company said.

Both companies will attend the upcoming American Thoracic Society International Conference in San Francisco, where the trial study will be featured in the Clinical Trial Awareness section, according to a statement.